|
Cholestasis
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Integrative ""-Omics"" Analysis in Primary Human Hepatocytes Unravels Persistent Mechanisms of Cyclosporine A-Induced Cholestasis."
|
27989131 |
2016 |
|
Amphetamine-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Genome-wide association for methamphetamine dependence: convergent results from 2 samples.
|
18316681 |
2008 |
|
Amphetamine Addiction
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association for methamphetamine dependence: convergent results from 2 samples.
|
18316681 |
2008 |
|
Amphetamine Abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association for methamphetamine dependence: convergent results from 2 samples.
|
18316681 |
2008 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Remote ischaemic conditioning for myocardial infarction or elective PCI: systematic review and meta-analyses of randomised trials.
|
29911392 |
2020 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, higher incidence of repeat revascularization after PCI in diabetic AMI patients a major concern until recently.
|
31420948 |
2020 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
AT1R (rs 5182) CT genotype is mildly associated with STEMI (OR = 1.1), but also prone to have PCI after ACS attack (OR = 1.6) while TT genotype has a risk to get less improvement (OR = 1.8).
|
31195108 |
2020 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe the incidence, timing, and characteristics of stent thrombosis and its consequences in patients with atrial fibrillation (AF) in the AUGUSTUS trial<sup>1</sup> who received a coronary stent during their qualifying admission (acute coronary syndrome [ACS] or elective percutaneous coronary intervention [PCI]) and the randomized treatment effects of low-dose aspirin (compared with placebo) and apixaban (compared with vitamin K antagonist [VKA]) on the risk of stent thrombosis.
|
31707833 |
2020 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The indication for PCI was chronic stable angina in 46.1% (n=26), non-ST elevation acute coronary syndrome (NSTEACS) in 33.3% (n=18) and ST-elevation myocardial infarction (STEMI) in 18.5% (n=10) of patients.
|
31130523 |
2020 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the transition from fibrinolysis to primary PCI, the HERO trials help refine STEMI ECG interpretation and Q wave analysis potentially alters future management.
|
30117751 |
2020 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From 434,172 low-risk, uncomplicated ACS patients eligible for early discharge (STEMI 35%, UA/NSTEMI 65%) from the Premier database, we identified ACS care pathways, by stratifying low-risk, uncomplicated STEMI and UA/NSTEMI patients by access site for PCI (trans-radial intervention [TRI] vs transfemoral intervention [TFI]) and by length of stay (LOS).
|
31812224 |
2020 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AT1R (rs 5182) CT genotype is mildly associated with STEMI (OR = 1.1), but also prone to have PCI after ACS attack (OR = 1.6) while TT genotype has a risk to get less improvement (OR = 1.8).
|
31195108 |
2020 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
The application of the retrograde approach has dramatically improved success rates of CTO PCI.
|
30912215 |
2020 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
As confirmed by our results, FFR and CFR are complementary; they could jointly contribute to better PCI guidance through the CFR-to-FFR ratio in patients with coronary artery disease.
|
30616240 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twelve (86%) patients underwent PCI for stable coronary artery disease and 2 (14%) had unstable angina.
|
31175527 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to examine the impact of AKI and its predictors in diabetic patients with multivessel coronary artery disease undergoing PCI vs. CABG.
|
31230933 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
They dwell on the 'either/or' decision for selected patients suitable for both treatments, but provide little guidance for the majority of 'real world' patients with comorbidities precluding CABG, or complex coronary heart disease precluding PCI.
|
30846525 |
2019 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to examine the impact of AKI and its predictors in diabetic patients with multivessel coronary artery disease undergoing PCI vs. CABG.
|
31230933 |
2019 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
They dwell on the 'either/or' decision for selected patients suitable for both treatments, but provide little guidance for the majority of 'real world' patients with comorbidities precluding CABG, or complex coronary heart disease precluding PCI.
|
30846525 |
2019 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate the value of Ang-2 in predicting cardiovascular events after elective PCI.This prospective study enrolled 97 patients with CHD who underwent elective PCI from 2013 to 2014.
|
30702576 |
2019 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
As confirmed by our results, FFR and CFR are complementary; they could jointly contribute to better PCI guidance through the CFR-to-FFR ratio in patients with coronary artery disease.
|
30616240 |
2019 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twelve (86%) patients underwent PCI for stable coronary artery disease and 2 (14%) had unstable angina.
|
31175527 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
So we evaluated the efficacy of the prasugrel/ticagrelor in patients with myocardial infarction (MI) and diabetes, a more high-risk patients group.From the Korea Acute Myocardial Infarction Registry-National Institute of Health, 3985 patients with MI and diabetes who underwent PCI were enrolled between November 2011 and December 2015.
|
30882670 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
At 36 months MV PCI was associated with similar incidence of the composite endpoint (all-cause death, non-fatal myocardial infarction [MI], ACS-driven, revascularisation, or stroke) in both Cox proportional hazards model (hazard ratio [HR] 1.26; 95% confidence interval [CI] 0.75-2.11; p = 0.39) and propensity matched analysis (HR 1.28; 95% CI 0.75-2.21; p = 0.36).
|
30251246 |
2019 |